Salvinorin B, kappa-opioid DREADD (KORD) agonist
Be the first to review this product! 리뷰 제출
|
(0 출판물)
MW 390.4 Da, Purity >98%. A potent and selective κ-opioid DREADD (KORD) agonist. DREADDs are chemogenetic tools widely used to remotely control cellular signaling, neuronal activity and behavior. Displays no analgesic or ataxic effects in wild type mice.
대체 명칭 보기
K-OR-1, Kappa opioid receptor, Kappa-type opioid receptor, OPRK 1, OPRK_HUMAN, Opiate receptor kappa 1, Opioid receptor, kappa 1, Oprk2, R21
제품 세부 정보
This product is manufactured by BioVision, an Abcam company and was previously called B1923 Salvinorin B. B1923-5 is the same size as the 5 mg size of ab235503.
Protect from air and light.
특성 및 보관 정보
배송 시 보관 조건
적절한 단기 보관 조건
적절한 장기 보관 조건
보관 정보
취급 방법
Need more advice on solubility, usage and handling? Please visit our our product support page for more details.
|
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
추가 정보
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Kappa opioid receptors mediate pain perception mood regulation and stress response. They form part of a larger receptor family the G-protein coupled receptors (GPCRs) which are critical in cellular signaling. Activation of these receptors can produce analgesic effects differing from other opioid receptors due to their unique mechanism of action. Kappa receptors interact with endogenous ligands called dynorphins which are peptide neurotransmitters involved in natural pain relief processes.
Pathways
Kappa opioid receptors are integral to the dopaminergic and serotonergic pathways. In the dopaminergic pathway kappa receptors reduce dopamine release influencing the reward system and potentially affecting addiction behaviors. In the serotonergic pathway they modulate serotonin levels connecting to mood and anxiety regulation. These pathways also involve proteins like the mu-opioid receptor and delta-opioid receptor which along with kappa receptors form a complex regulatory network.
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com